Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

ClinicalTrials.gov ID: NCT00941031

Public ClinicalTrials.gov record NCT00941031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Study identification

NCT ID
NCT00941031
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
404 participants

Conditions and interventions

Interventions

  • AIN457 Drug
  • AIN457A Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2009
Primary completion
Nov 30, 2010
Completion
Nov 30, 2010
Last update posted
Aug 19, 2015

2009 – 2010

United States locations

U.S. sites
29
U.S. states
20
U.S. cities
28
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35233
Novartis Investigative Site Little Rock Arkansas 72205
Novartis Investigative Site Pasadena California 91105
Novartis Investigative Site San Diego California 92123
Novartis Investigative Site Newnan Georgia 30263
Novartis Investigative Site Snellville Georgia 30078
Novartis Investigative Site Champaign Illinois 61820
Novartis Investigative Site Springfield Illinois 62703
Novartis Investigative Site Evansville Indiana 47713
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Louisville Kentucky 40217
Novartis Investigative Site Boston Massachusetts 02111
Novartis Investigative Site Clinton Twp. Michigan 48038
Novartis Investigative Site Detroit Michigan 48202
Novartis Investigative Site Minneapolis Minnesota 55455
Novartis Investigative Site St Louis Missouri 63117
Novartis Investigative Site Omaha Nebraska 68131
Novartis Investigative Site Omaha Nebraska 68144
Novartis Investigative Site Henderson Nevada 89052
Novartis Investigative Site New York New York 10029
Novartis Investigative Site Rochester New York 14623
Novartis Investigative Site High Point North Carolina 27262
Novartis Investigative Site Lake Oswego Oregon 97035
Novartis Investigative Site Portland Oregon 97210
Novartis Investigative Site Philadelphia Pennsylvania 19104
Novartis Investigative Site Austin Texas 78759
Novartis Investigative Site Dallas Texas 75204
Novartis Investigative Site Charlottesville Virginia 22911
Novartis Investigative Site Lynchburg Virginia 24501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00941031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2015 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00941031 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →